Invention Grant
- Patent Title: Oral dosage form comprising rifaximin in form beta
-
Application No.: US16076772Application Date: 2018-04-25
-
Publication No.: US11052071B2Publication Date: 2021-07-06
- Inventor: Franz Xaver Schwarz
- Applicant: Sandoz AG
- Applicant Address: CH Basel
- Assignee: Sandoz AG
- Current Assignee: Sandoz AG
- Current Assignee Address: CH Basel
- Agency: Luedeka Neely Group, P.C.
- Priority: EP17168281 20170426
- International Application: PCT/EP2018/060547 WO 20180425
- International Announcement: WO2018/197538 WO 20181101
- Main IPC: A61K31/437
- IPC: A61K31/437 ; A61K9/00 ; A61K9/20
Abstract:
The present invention relates to an oral dosage form containing rifaximin in form beta, wherein the oral dosage form provides delayed release of the active pharmaceutical agent. Further, the invention relates to the preparation of an oral dosage form, preferably a tablet.
Public/Granted literature
- US20190388404A1 Oral Dosage Form Comprising Rifaximin in Form Beta Public/Granted day:2019-12-26
Information query
IPC分类:
